Accueil>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Potassium Channel>>SKA-111

SKA-111

Catalog No.GC70205

SKA-111 est un activateur sélectif de potassium phannel KCa 3.1, évoque l’hyperpolarisation de la membrane KCa 3.1 dans la cellule endothéliale porcine.

Products are for research use only. Not for human use. We do not sell to patients.

SKA-111 Chemical Structure

Cas No.: 1369170-24-0

Taille Prix Stock Qté
5 mg
171,00 $US
En stock
10 mg
288,00 $US
En stock
25 mg
576,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
SKA-111 is a selective activator of potassium phannel KCa 3.1 , evokes KCa 3.1 membrane hyperpolarization in porcine endothelial cell. SKA-111 is capable of improving Bradykinin -induced coronary dilations in the isolated rat heart and can be used for cardiovascular disease research.

SKA-111 (1 μM, 5 min) evokes KCa 3.1 membrane hyperpolarization in porcine endothelial cell[1].
SKA-111 (1 μM, 5 min) induces significantly augmented the Bradykinin-induced endothelium-derived hyperpolarization (EDH)-type relaxation in large porcine coronary arteries (PCA) [1].

SKA-111 (1 μM for cardiac perfusion) improves Bradykinin -induced coronary dilations in the isolated rat heart[1].

References:
[1]. Oliván-Viguera A, et.al. Vascular Reactivity Profile of Novel KCa 3.1-Selective Positive-Gating Modulators in the Coronary Vascular Bed. Basic Clin Pharmacol Toxicol. 2016 Aug;119(2):184-92.

Avis

Review for SKA-111

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SKA-111

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.